Lilly Korea announced on the 1st that its GIP/GLP-1 dual-acting agent, Mounjaro (tirzepatide), has received approval from the Ministry of Food and Drug Safety (MFDS) as an adjunct for chronic weight management.

Mounjaro is the first and, to date, the only (as of July 2024) GIP/GLP-1 dual receptor agonist available. It selectively binds to and activates both GIP and GLP-1 receptors, the targets of endogenous GIP and GLP-1, to lower fasting and postprandial blood glucose concentrations and reduce body weight and body fat.

GIP and GLP-1 are two primary incretin hormones that stimulate insulin secretion, improve insulin sensitivity, reduce glucagon secretion, regulate appetite, and maintain